里赫特转变（RT）是一种罕见的情况，其表示从潜在的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤中发展出侵袭性淋巴瘤。对RT的管理仍然具有挑战性，需要结合治疗策略以实现良好的结果。传统的RT治疗选择涉及强化化疗方案，通常因疾病的高风险性而获得有限的成功。然而，对RT发病机制认识的最新进展导致了新型靶向治疗的出现，表现出有希望的结果。非共价布鲁顿酪氨酸激酶抑制剂、T细胞结合双特异性抗体、嵌合抗原受体T细胞和共轭的单克隆抗体可能在以多靶向方式联合使用时对RT有改善结果的希望。需要进一步的前瞻性随机试验和协作努力，以优化治疗算法并最终改善这种令人沮丧的疾病患者的结果。该综述全面概述了RT当前的治疗选择。版权所有©2023。由爱思唯尔公司出版。

Richter's transformation (RT) is a rare condition, represented by the development of an aggressive lymphoma arising from underlying chronic lymphocytic leukemia/small lymphocytic lymphoma. The management of RT remains challenging, necessitating combined therapeutic strategies to achieve favorable outcomes. Traditional treatment options for RT have involved intensive chemotherapy regimens, often with limited success due to the high-risk nature of the disease. However, recent advances in the understanding of RT pathogenesis have led to the emergence of novel targeted therapies that show promising results. Noncovalent Bruton tyrosine kinase inhibitors, T-cell-engaging bispecific antibodies, chimeric antigen receptor T-cells, and conjugated monoclonal antibodies may hold promise for improved outcomes in RT, especially when combined in a multitargeted fashion. Further prospective randomized trials and collaborative efforts are warranted to optimize treatment algorithm and ultimately improve patient outcomes in this dismal condition. This review provides a comprehensive overview of the current treatment options for RT.Copyright © 2023. Published by Elsevier Inc.